Search Results

You are looking at 201 - 210 of 530 items for :

  • "pathology" x
  • Refine by Access: All x
Clear All
Full access

Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Joseph Chao, David Cooke, Carlos Corvera, Prajnan Das, Peter C. Enzinger, Thomas Enzler, Paul Fanta, Farhood Farjah, Hans Gerdes, Michael K. Gibson, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Sunnie Kim, Lawrence R. Kleinberg, Samuel J. Klempner, Jill Lacy, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Mary F. Mulcahy, Darryl Outlaw, Haeseong Park, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Scott Reznik, Robert E. Roses, Vivian E. Strong, Stacey Su, Hanlin L. Wang, Georgia Wiesner, Christopher G. Willett, Danny Yakoub, Harry Yoon, Nicole McMillian, and Lenora A. Pluchino

pathology assessments to establish cTNM and ypTNM stages has never been validated and may not be appropriate. Therefore, new cTNM and ypTNM stage groupings and prognostic information were added to the eighth edition to overcome these issues. New clinical

Full access

Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel

about the reliability of biomarker testing in breast cancer. ASCO, the College of American Pathology, and NCCN issued technology assessments on methods to assure high-quality performance and interpretation of ER, PR, and HER2 testing. 3 - 6

Full access

George Handzo, Jill M. Bowden, and Stephen King

publication of the third edition of the NCP guidelines. The panel chose “distress” as the focus of the 1997 NCCN Guidelines because that term did not represent or infer any kind of pathology. Efforts were made to describe distress as a normally expected

Full access

M. Zach Koontz, Brendan M. Visser, and Pamela L. Kunz

her tumor 3 weeks after discontinuing imatinib. Because of the location of the tumor and involvement of the SMV, a Whipple procedure was required. However, it was believed that the neoadjuvant imatinib made this procedure possible. Pathology revealed a

Full access

Rajinder S. Grover, Kemp Kernstine, and Amrita Krishnan

final pathology. Figure 1 CT of the face, neck, and torso, and PET/CT showing FDG uptake. CT of the chest with contrast (A) reveals a large mass surrounding the distal esophagus measuring 6.0 x 3.7 cm and extending to the gastroesophageal

Full access

Brian J. Williams, Daniel M.S. Raper, Erin Godbout, T. David Bourne, Daniel M. Prevedello, Amin B. Kassam, and Deric M. Park

against chordoma. 46 Finally, brachyury, a histologic marker for chordoma, may also drive chordoma pathology. Transient genetic knockdown of brachyury in chordoma cells was found to induce differentiation and senescence. 47 Furthermore, brachyury has

Full access

Michael Cecchini, Jeffrey Sklar, and Jill Lacy

neoadjuvant FOLFIRINOX followed by pancreaticoduodenectomy with negative margins and 6 cycles of adjuvant FOLFIRINOX. Surgical pathology revealed ypT3N1Mx (stage IIB) adenocarcinoma. Eight months after completion of adjuvant therapy, PET imaging revealed

Full access

Mod C. Chandhanayingyong, Nicholas M. Bernthal, Piti Ungarreevittaya, Scott D. Nelson, Sant P. Chawla, and Arun S. Singh

. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease . Hum Mol Genet 1997 ; 6 : 1383 – 1387 . 3 Starink TM Hausman R . The cutaneous pathology of extrafacial lesions in Cowden's disease . J Cutan Pathol 1984 ; 11 : 338

Full access

Mariam Naveed, Meredith Clary, Chul Ahn, Nisa Kubiliun, Deepak Agrawal, Byron Cryer, Caitlin Murphy, and Amit G. Singal

, gastrointestinal symptoms), laboratory data (eg, iron deficiency anemia), radiologic data (eg, bowel thickening on imaging), and prior pathology and colonoscopy data (eg, history of adenomas). Family history of colon cancer denoting high-risk screening was defined

Full access

Antoine Eskander, Qing Li, Jiayue Yu, Julie Hallet, Natalie G. Coburn, Anna Dare, Kelvin K.W. Chan, Simron Singh, Ambica Parmar, Craig C. Earle, Lauren Lapointe-Shaw, Monika K. Krzyzanowska, Timothy P. Hanna, Antonio Finelli, Alexander V. Louie, Nicole Look Hong, Jonathan C. Irish, Ian J. Witterick, Alyson Mahar, Christopher W. Noel, David R. Urbach, Daniel I. McIsaac, Danny Enepekides, and Rinku Sutradhar

from September 25, 2016, to September 26, 2020, were identified using the Ontario Cancer Registry (OCR); this database consists of all cancers diagnosed in the province since 1964 and has a >95% capture of incident cancers. 14 , 15 All pathology